{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:04:00Z","timestamp":1783735440522,"version":"3.55.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11606-010-1569-5","type":"journal-article","created":{"date-parts":[[2011,1,3]],"date-time":"2011-01-03T15:33:48Z","timestamp":1294068828000},"page":"326-339","source":"Crossref","is-referenced-by-count":13,"title":["Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection"],"prefix":"10.1007","volume":"26","author":[{"given":"Tatyana A.","family":"Shamliyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasma","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Min","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"issue":"5 Suppl","key":"1569_CR1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/hep.22946","volume":"49","author":"MF Sorrell","year":"2009","unstructured":"Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49(5 Suppl):S4\u201312.","journal-title":"Hepatology"},{"key":"1569_CR2","first-page":"1","volume":"174","author":"TJ Wilt","year":"2008","unstructured":"Wilt TJ, Shamliyan T, Shaukat A, et al. Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep). 2008;174:1\u2013671.","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"issue":"5 Suppl","key":"1569_CR3","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1002\/hep.22977","volume":"49","author":"JJ Feld","year":"2009","unstructured":"Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S96\u2013102.","journal-title":"Hepatology"},{"issue":"2","key":"1569_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-150-2-200901200-00101","volume":"150","author":"TA Shamliyan","year":"2009","unstructured":"Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150(2):111\u201324.","journal-title":"Ann Intern Med"},{"issue":"10","key":"1569_CR5","doi-asserted-by":"crossref","first-page":"JC5","DOI":"10.7326\/0003-4819-150-10-200905190-02006","volume":"150","author":"J Reichen","year":"2009","unstructured":"Reichen J. ACP Journal Club. Review: evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B. Ann Intern Med. 2009;150(10):JC5\u20136.","journal-title":"Ann Intern Med"},{"key":"1569_CR6","unstructured":"National Institutes of Health (U.S.). NIH consensus development conference management of hepatitis B. [Bethesda, Md.: National Institutes of Health; 2008: Retieved October 1, 2010 http:\/\/videocast.nih.gov\/launch.asp?14714 Retrieved October 1, 2010 http:\/\/videocast.nih.gov\/launch.asp?14712 Retrieved October 1, 2010 http:\/\/videocast.nih.gov\/launch.asp?14719"},{"issue":"5 Suppl","key":"1569_CR7","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","volume":"49","author":"CJ Chen","year":"2009","unstructured":"Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72\u201384.","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"1569_CR8","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","volume":"49","author":"R Perrillo","year":"2009","unstructured":"Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S103\u201311.","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"1569_CR9","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1002\/hep.22920","volume":"49","author":"JL Dienstag","year":"2009","unstructured":"Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S112\u201321.","journal-title":"Hepatology"},{"key":"1569_CR10","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"J Higgins","year":"2008","unstructured":"Higgins J, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell; 2008."},{"issue":"3","key":"1569_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/0003-4819-151-3-200908040-00125","volume":"151","author":"HC Sox","year":"2009","unstructured":"Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151(3):203\u20135.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1569_CR12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jclinepi.2008.06.009","volume":"63","author":"J Slutsky","year":"2010","unstructured":"Slutsky J, Atkins D, Chang S, Sharp BA. AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):481\u20133.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1569_CR13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jclinepi.2009.05.005","volume":"63","author":"M Helfand","year":"2010","unstructured":"Helfand M, Balshem H. AHRQ series paper 2: principles for developing guidance: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):484\u201390.","journal-title":"J Clin Epidemiol"},{"issue":"3 Suppl","key":"1569_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-3797(01)00261-6","volume":"20","author":"RP Harris","year":"2001","unstructured":"Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21\u201335.","journal-title":"Am J Prev Med"},{"key":"1569_CR15","unstructured":"Cochrane Collaboration. The Cochrane library. Retrieved October 1, 2010 from http:\/\/www3.interscience.wiley.com\/cgi-bin\/mrwhome\/106568753\/HOME"},{"key":"1569_CR16","unstructured":"United States. Food and Drug Administration. MedWatch. MedWatch online voluntary reporting form (3500). [Rockville, Md.]: Food and Drug Administration, MedWatch; 2002. Retrieved October 1, 2010 from http:\/\/purl.access.gpo.gov\/GPO\/LPS39966 and retrieved October 1, 2010 from http:\/\/purl.access.gpo.gov\/GPO\/LPS81658"},{"issue":"5","key":"1569_CR17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0399-8320(07)89420-6","volume":"31","author":"H Fontaine","year":"2007","unstructured":"Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol. 2007;31(5):504\u20139.","journal-title":"Gastroenterol Clin Biol"},{"issue":"2","key":"1569_CR18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507\u201339.","journal-title":"Hepatology"},{"issue":"8","key":"1569_CR19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4065\/82.8.967","volume":"82","author":"S Pungpapong","year":"2007","unstructured":"Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82(8):967\u201375.","journal-title":"Mayo Clin Proc"},{"key":"1569_CR20","first-page":"1","volume":"47","author":"S West","year":"2002","unstructured":"West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess. 2002;47:1\u201311.","journal-title":"Evid Rep Technol Assess"},{"issue":"9193","key":"1569_CR21","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896\u2013900.","journal-title":"Lancet"},{"key":"1569_CR22","doi-asserted-by":"crossref","DOI":"10.1002\/0470854200","volume-title":"Meta-analysis of Controlled Clinical Trials","author":"A Whitehead","year":"2002","unstructured":"Whitehead A. Meta-analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons; 2002."},{"issue":"3","key":"1569_CR23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"1569_CR24","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. Feb 6 2006.","DOI":"10.1002\/sim.2514"},{"issue":"2","key":"1569_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/bimj.200510175","volume":"48","author":"G Knapp","year":"2006","unstructured":"Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. Biom J. 2006;48(2):271\u201385.","journal-title":"Biom J"},{"issue":"2","key":"1569_CR26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","volume":"53","author":"A Thornton","year":"2000","unstructured":"Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53(2):207\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1569_CR27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1472-6963-5-25","volume":"5","author":"D Atkins","year":"2005","unstructured":"Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res. 2005;5(1):25.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1569_CR28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","volume":"4","author":"D Atkins","year":"2004","unstructured":"Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.","journal-title":"BMC Health Serv Res"},{"key":"1569_CR29","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926","volume-title":"Systematic Reviews in Health Care","author":"M Egger","year":"2001","unstructured":"Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. London: NetLibrary, Inc. BMJ Books; 2001."},{"issue":"2","key":"1569_CR30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/01632780122034858","volume":"24","author":"S Ebrahim","year":"2001","unstructured":"Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof. 2001;24(2):152\u201364.","journal-title":"Eval Health Prof"},{"issue":"7168","key":"1569_CR31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. Br Med J (Clinical research). 1998;317(7168):1309\u201312.","journal-title":"Br Med J (Clinical research)"},{"issue":"5","key":"1569_CR32","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jclinepi.2008.06.007","volume":"63","author":"R Chou","year":"2010","unstructured":"Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):502\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1569_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2288-9-80","volume":"9","author":"BC Wallace","year":"2009","unstructured":"Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.","journal-title":"BMC Med Res Methodol"},{"key":"1569_CR34","unstructured":"Red book 2008 pharmacy\u2019s fundamental reference. 2008 ed. Montvale, N.J.: Thomson; 2008."},{"issue":"15","key":"1569_CR35","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1517\/14656566.9.15.2673","volume":"9","author":"JH You","year":"2008","unstructured":"You JH, Chan FW. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opin Pharmacother. 2008;9(15):2673\u201381.","journal-title":"Expert Opin Pharmacother"},{"issue":"35","key":"1569_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13350","volume":"13","author":"J Jones","year":"2009","unstructured":"Jones J, Shepherd J, Baxter L, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess. 2009;13(35):1\u2013172. iii.","journal-title":"Health Technol Assess"},{"issue":"1","key":"1569_CR37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/hep.510300113","volume":"30","author":"HL Janssen","year":"1999","unstructured":"Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1999;30(1):238\u201343.","journal-title":"Hepatology"},{"issue":"4","key":"1569_CR38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","volume":"46","author":"SW Schalm","year":"2000","unstructured":"Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46(4):562\u20138.","journal-title":"Gut"},{"issue":"3","key":"1569_CR39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0168-8278(01)00145-3","volume":"35","author":"G Barbaro","year":"2001","unstructured":"Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001;35(3):406\u201311.","journal-title":"J Hepatol"},{"issue":"1","key":"1569_CR40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","volume":"36","author":"RP Perrillo","year":"2002","unstructured":"Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36(1):186\u201394.","journal-title":"Hepatology"},{"issue":"6","key":"1569_CR41","first-page":"1425","volume":"36","author":"CT Wai","year":"2002","unstructured":"Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36(6):1425\u201330.","journal-title":"Hepatology"},{"issue":"5","key":"1569_CR42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00042737-200305000-00006","volume":"15","author":"YH Chung","year":"2003","unstructured":"Chung YH, Song BC, Lee GC, et al. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial. Eur J Gastroenterol Hepatol. 2003;15(5):489\u201393.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"1569_CR43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0168-8278(03)00076-X","volume":"38","author":"ER Schiff","year":"2003","unstructured":"Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24\u00a0weeks of lamivudine\/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38(6):818\u201326.","journal-title":"J Hepatol"},{"issue":"12","key":"1569_CR44","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1086\/375085","volume":"36","author":"K Yalcin","year":"2003","unstructured":"Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis. 2003;36(12):1516\u201322.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1569_CR45","first-page":"396","volume":"1","author":"C Niederau","year":"1992","unstructured":"Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med. 1992;1(7):396\u2013402.","journal-title":"Eur J Med"},{"issue":"5","key":"1569_CR46","first-page":"317","volume":"82","author":"SC Robson","year":"1992","unstructured":"Robson SC, Brice E, van Rensburg C, Kannemeyer J, Hift RJ, Kirsch RE. Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study. S Afr Med J. 1992;82(5):317\u201320.","journal-title":"S Afr Med J"},{"issue":"3","key":"1569_CR47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/135965350400900306","volume":"9","author":"US Akarca","year":"2004","unstructured":"Akarca US, Ersoz G, Gunsar F, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther. 2004;9(3):325\u201334.","journal-title":"Antivir Ther"},{"issue":"12","key":"1569_CR48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1440-1746.2004.03464.x","volume":"19","author":"MK Jang","year":"2004","unstructured":"Jang MK, Chung YH, Choi MH, et al. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol. 2004;19(12):1363\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1569_CR49","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/0016-5085(92)90337-X","volume":"102","author":"AS Lok","year":"1992","unstructured":"Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102(6):2091\u20137.","journal-title":"Gastroenterology"},{"issue":"37","key":"1569_CR50","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3748\/wjg.v11.i37.5882","volume":"11","author":"M Economou","year":"2005","unstructured":"Economou M, Manolakopoulos S, Trikalinos TA, et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol. 2005;11(37):5882\u20137.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1569_CR51","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1572-0241.2005.00247.x","volume":"100","author":"SK Sarin","year":"2005","unstructured":"Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005;100(11):2463\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1569_CR52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkl385","volume":"58","author":"M Shi","year":"2006","unstructured":"Shi M, Wang RS, Zhang H, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006;58(5):1031\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1569_CR53","first-page":"145","volume":"14","author":"G Scotto","year":"2006","unstructured":"Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Angarano G. Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. Infez Med. 2006;14(3):145\u201351.","journal-title":"Infez Med"},{"issue":"20","key":"1569_CR54","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3748\/wjg.v13.i20.2878","volume":"13","author":"HY Lu","year":"2007","unstructured":"Lu HY, Zhuang LW, Yu YY, et al. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol. 2007;13(20):2878\u201382.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1569_CR55","first-page":"20","volume":"70","author":"F Akyuz","year":"2007","unstructured":"Akyuz F, Kaymakoglu S, Demir K, et al. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg. 2007;70(1):20\u20134.","journal-title":"Acta Gastroenterol Belg"},{"issue":"Suppl 1","key":"1569_CR56","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/0168-8278(90)90175-Q","volume":"11","author":"V Perez","year":"1990","unstructured":"Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol. 1990;11(Suppl 1):S113\u20137.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1569_CR57","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/0168-8278(90)90180-Y","volume":"11","author":"S Hadziyannis","year":"1990","unstructured":"Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative\/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990;11(Suppl 1):S133\u20136.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1569_CR58","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/0168-8278(90)90181-P","volume":"11","author":"R Muller","year":"1990","unstructured":"Muller R, Baumgarten R, Markus R, et al. Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol. 1990;11(Suppl 1):S137\u201340.","journal-title":"J Hepatol"},{"issue":"5","key":"1569_CR59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/1120009X.1990.11739035","volume":"2","author":"I Waked","year":"1990","unstructured":"Waked I, Amin M, Abd el Fattah S, Osman LM, Sabbour MS. Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 1990;2(5):310\u20138.","journal-title":"J Chemother"},{"issue":"5","key":"1569_CR60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","volume":"323","author":"RP Perrillo","year":"1990","unstructured":"Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323(5):295\u2013301.","journal-title":"N Engl J Med"},{"issue":"6","key":"1569_CR61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0168-8278(05)80143-6","volume":"20","author":"JP Zarski","year":"1994","unstructured":"Zarski JP, Causse X, Cohard M, Cougnard J, Trepo C. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol. 1994;20(6):735\u201341.","journal-title":"J Hepatol"},{"issue":"2","key":"1569_CR62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0168-8278(05)80054-6","volume":"20","author":"J Reichen","year":"1994","unstructured":"Reichen J, Bianchi L, Frei PC, Male PJ, Lavanchy D, Schmid M. Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. J Hepatol. 1994;20(2):168\u201374.","journal-title":"J Hepatol"},{"issue":"11","key":"1569_CR63","first-page":"1887","volume":"88","author":"AM Bisceglie Di","year":"1993","unstructured":"Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol. 1993;88(11):1887\u201392.","journal-title":"Am J Gastroenterol"},{"issue":"2 Suppl","key":"1569_CR64","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1136\/gut.34.2_Suppl.S91","volume":"34","author":"V Perez","year":"1993","unstructured":"Perez V, Findor J, Tanno H, Sorda J. A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. Gut. 1993;34(2 Suppl):S91\u20134.","journal-title":"Gut"},{"issue":"2 Suppl","key":"1569_CR65","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1136\/gut.34.2_Suppl.S97","volume":"34","author":"R Muller","year":"1993","unstructured":"Muller R, Baumgarten R, Markus R, et al. Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut. 1993;34(2 Suppl):S97\u20138.","journal-title":"Gut"},{"issue":"Suppl 1","key":"1569_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2893.1997.tb00157.x","volume":"4","author":"JM Lopez-Alcorocho","year":"1997","unstructured":"Lopez-Alcorocho JM, Bartolome J, Cotonat T, Carreno V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12\u00a0months of therapy. J Viral Hepat. 1997;4(Suppl 1):27\u201332.","journal-title":"J Viral Hepat."},{"issue":"6","key":"1569_CR67","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.510260634","volume":"26","author":"P Lampertico","year":"1997","unstructured":"Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26(6):1621\u20135.","journal-title":"Hepatology."},{"issue":"6","key":"1569_CR68","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0168-8278(98)80338-3","volume":"28","author":"D Mutimer","year":"1998","unstructured":"Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol. 1998;28(6):923\u20139.","journal-title":"J Hepatol"},{"issue":"5","key":"1569_CR69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","volume":"56","author":"F Bonino","year":"2007","unstructured":"Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56(5):699\u2013705.","journal-title":"Gut"},{"issue":"4","key":"1569_CR70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","volume":"10","author":"WG Cooksley","year":"2003","unstructured":"Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40\u00a0kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis. 2003;10(4):298\u2013305.","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"1569_CR71","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206\u201317.","journal-title":"N Engl J Med"},{"issue":"26","key":"1569_CR72","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682\u201395.","journal-title":"N Engl J Med"},{"issue":"5","key":"1569_CR73","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.mcg.0000225586.78330.60","volume":"41","author":"M Cindoruk","year":"2007","unstructured":"Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007;41(5):513\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"1569_CR74","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800\u20137.","journal-title":"N Engl J Med"},{"issue":"26","key":"1569_CR75","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","volume":"352","author":"SJ Hadziyannis","year":"2005","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352(26):2673\u201381.","journal-title":"N Engl J Med"},{"issue":"6","key":"1569_CR76","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology. 2006;131(6):1743\u201351.","journal-title":"Gastroenterology"},{"issue":"9","key":"1569_CR77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","volume":"348","author":"P Marcellin","year":"2003","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"1569_CR78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","volume":"44","author":"M Zeng","year":"2006","unstructured":"Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108\u201316.","journal-title":"Hepatology"},{"issue":"1","key":"1569_CR79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","volume":"125","author":"C Westland","year":"2003","unstructured":"Westland C, Delaney Wt, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107\u201316.","journal-title":"Gastroenterology"},{"issue":"1","key":"1569_CR80","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/jhep.2003.50288","volume":"38","author":"CE Westland","year":"2003","unstructured":"Westland CE, Yang H, Delaney WEt, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003;38(1):96\u2013103.","journal-title":"Hepatology"},{"issue":"3","key":"1569_CR81","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","volume":"66","author":"H Izzedine","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66(3):1153\u20138.","journal-title":"Kidney Int"},{"issue":"1","key":"1569_CR82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","volume":"126","author":"R Perrillo","year":"2004","unstructured":"Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126(1):81\u201390.","journal-title":"Gastroenterology"},{"issue":"12","key":"1569_CR83","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1007\/s10620-006-9718-8","volume":"52","author":"M Akyildiz","year":"2007","unstructured":"Akyildiz M, Gunsar F, Ersoz G, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci. 2007;52(12):3444\u20137.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1569_CR84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","volume":"126","author":"MG Peters","year":"2004","unstructured":"Peters MG, Hann HWH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91\u2013101.","journal-title":"Gastroenterology"},{"issue":"11","key":"1569_CR85","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","volume":"147","author":"HL Chan","year":"2007","unstructured":"Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745\u201354.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1569_CR86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","volume":"101","author":"HJ Flink","year":"2006","unstructured":"Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. American J Gastroenterol. 2006;101(2):297\u2013303.","journal-title":"American J Gastroenterol"},{"issue":"9454","key":"1569_CR87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1569_CR88","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","volume":"46","author":"EH Buster","year":"2007","unstructured":"Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46(2):388\u201394.","journal-title":"Hepatology"},{"issue":"3","key":"1569_CR89","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/hep.21302","volume":"44","author":"MJ Borg ter","year":"2006","unstructured":"ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology. 2006;44(3):721\u20137.","journal-title":"Hepatology"},{"issue":"11","key":"1569_CR90","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1572-0241.2006.00812.x","volume":"101","author":"HJ Flink","year":"2006","unstructured":"Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006;101(11):2523\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1569_CR91","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","volume":"21","author":"M Zonneveld van","year":"2005","unstructured":"van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21(9):1163\u201371.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1569_CR92","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","volume":"54","author":"HJ Flink","year":"2005","unstructured":"Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005;54(11):1604\u20139.","journal-title":"Gut"},{"issue":"4","key":"1569_CR93","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1478-3231.2006.01257.x","volume":"26","author":"M Zonneveld van","year":"2006","unstructured":"van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006;26(4):399\u2013405.","journal-title":"Liver Int"},{"issue":"6","key":"1569_CR94","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.20695","volume":"41","author":"HL Chan","year":"2005","unstructured":"Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005;41(6):1357\u201364.","journal-title":"Hepatology"},{"issue":"4","key":"1569_CR95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","volume":"142","author":"HL Chan","year":"2005","unstructured":"Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142(4):240\u201350.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1569_CR96","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1365-2036.2006.02948.x","volume":"23","author":"HL Chan","year":"2006","unstructured":"Chan HL, Tse AM, Zhang MD, et al. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther. 2006;23(12):1703\u201311.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1569_CR97","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/511042","volume":"44","author":"H Zhao","year":"2007","unstructured":"Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated\/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44(4):541\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1569_CR98","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011.","journal-title":"N Engl J Med"},{"issue":"10","key":"1569_CR99","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"6","key":"1569_CR100","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/gast.2002.37058","volume":"123","author":"CL Lai","year":"2002","unstructured":"Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831\u20138.","journal-title":"Gastroenterology"},{"issue":"4","key":"1569_CR101","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","volume":"129","author":"TT Chang","year":"2005","unstructured":"Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198\u2013209.","journal-title":"Gastroenterology"},{"issue":"7","key":"1569_CR102","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","volume":"130","author":"M Sherman","year":"2006","unstructured":"Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039\u201349.","journal-title":"Gastroenterology"},{"issue":"5","key":"1569_CR103","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"RG Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96\u00a0weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437\u201344.","journal-title":"Gastroenterology"},{"issue":"2","key":"1569_CR104","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"CL Lai","year":"2005","unstructured":"Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528\u201336.","journal-title":"Gastroenterology"},{"issue":"6","key":"1569_CR105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","volume":"35","author":"YO Kweon","year":"2001","unstructured":"Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35(6):749\u201355.","journal-title":"J Hepatol"},{"issue":"25","key":"1569_CR106","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3748\/wjg.v12.i25.4061","volume":"12","author":"CZ Ke","year":"2006","unstructured":"Ke CZ, Chen Y, Gong ZJ, et al. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J Gastroenterol. 2006;12(25):4061\u20133.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"1569_CR107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2005.02410.x","volume":"21","author":"MF Yuen","year":"2005","unstructured":"Yuen MF, Chow DH, Tsui K, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005;21(7):841\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1569_CR108","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1096-9071(200007)61:3<392::AID-JMV19>3.0.CO;2-V","volume":"61","author":"GB Yao","year":"2000","unstructured":"Yao GB. Management of hepatitis B in China. J Med Virol. 2000;61(3):392\u20137.","journal-title":"J Med Virol"},{"issue":"15","key":"1569_CR109","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"1569_CR110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","volume":"119","author":"YF Liaw","year":"2000","unstructured":"Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172\u201380.","journal-title":"Gastroenterology"},{"issue":"6","key":"1569_CR111","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","volume":"33","author":"NW Leung","year":"2001","unstructured":"Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3\u00a0years of therapy. Hepatology. 2001;33(6):1527\u201332.","journal-title":"Hepatology"},{"issue":"1","key":"1569_CR112","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","volume":"124","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105\u201317.","journal-title":"Gastroenterology"},{"issue":"17","key":"1569_CR113","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"1569_CR114","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2893.1998.00121.x","volume":"5","author":"P Honkoop","year":"1998","unstructured":"Honkoop P, de Man RA, Niesters HG, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatitis. 1998;5(5):307\u201312.","journal-title":"J Viral Hepatitis"},{"issue":"4","key":"1569_CR115","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1053\/gast.1997.v113.pm9322520","volume":"113","author":"F Nevens","year":"1997","unstructured":"Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997;113(4):1258\u201363.","journal-title":"Gastroenterology"},{"issue":"3","key":"1569_CR116","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135965350701200308","volume":"12","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345\u201353.","journal-title":"Antivir Ther"},{"issue":"5","key":"1569_CR117","first-page":"387","volume":"112","author":"G Yao","year":"1999","unstructured":"Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl). 1999;112(5):387\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"1569_CR118","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00535-005-1750-5","volume":"41","author":"YJ Kim","year":"2006","unstructured":"Kim YJ, Kim BG, Jung JO, Yoon JH, Lee HS. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol. 2006;41(3):240\u20139.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1569_CR119","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","volume":"29","author":"NC Tassopoulos","year":"1999","unstructured":"Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology. 1999;29(3):889\u201396.","journal-title":"Hepatology"},{"issue":"25","key":"1569_CR120","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"1569_CR121","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1\u00a0year of a randomized, double-blind trial. Hepatology. 2008;47(2):447\u201354.","journal-title":"Hepatology"},{"issue":"23","key":"1569_CR122","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442\u201355.","journal-title":"N Engl J Med"},{"issue":"2","key":"1569_CR123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61\u20138.","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"1569_CR124","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/hep.22929","volume":"49","author":"BC Taylor","year":"2009","unstructured":"Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology. 2009;49(5 Suppl):S85\u201395.","journal-title":"Hepatology"},{"issue":"1","key":"1569_CR125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.284.1.79","volume":"284","author":"TG McGinn","year":"2000","unstructured":"McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA. 2000;284(1):79\u201384.","journal-title":"JAMA"},{"issue":"21","key":"1569_CR126","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1001\/jama.283.21.2829","volume":"283","author":"FA McAlister","year":"2000","unstructured":"McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA. 2000;283(21):2829\u201336.","journal-title":"JAMA"},{"issue":"7438","key":"1569_CR127","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.328.7438.475","volume":"328","author":"I Chalmers","year":"2004","unstructured":"Chalmers I. Well informed uncertainties about the effects of treatments. Br Med J (Clinical research). 2004;328(7438):475\u20136.","journal-title":"Br Med J (Clinical research)"},{"issue":"5 Suppl","key":"1569_CR128","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49(5 Suppl):S174\u201384.","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"1569_CR129","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156\u201365.","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"1569_CR130","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S185\u201395.","journal-title":"Hepatology"},{"key":"1569_CR131","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. Feb 2009;50(2):227-242.","DOI":"10.1016\/j.jhep.2008.10.001"},{"issue":"2","key":"1569_CR132","first-page":"1","volume":"25","author":"EA Belongia","year":"2008","unstructured":"Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements. 2008;25(2):1\u201329.","journal-title":"NIH Consens State Sci Statements"},{"key":"1569_CR133","doi-asserted-by":"crossref","unstructured":"Dusheiko GM. Cost-effectiveness of oral treatments for chronic hepatitis B. J Hepatol. Aug 6 2009.","DOI":"10.1016\/j.jhep.2009.07.015"},{"key":"1569_CR134","doi-asserted-by":"crossref","unstructured":"Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. May 20 2009.","DOI":"10.1016\/j.jhep.2009.04.013"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-010-1569-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-010-1569-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-010-1569-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T18:20:41Z","timestamp":1685902841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-010-1569-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s11606-010-1569-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}